Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

eli lilly and company - glucagon - powder for injection - 10 mg

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - glucagon 9x, 12x, 30x, 60x - for the temporary relief of lethargy, weak memory or concentration, irritability, or nausea due to sensitivity to phenolic compounds found in foods or other products.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - glucagon hydrochloride 1mg (recombinant);  ;   - solution for injection - 1 mg - active: glucagon hydrochloride 1mg (recombinant)     excipient: lactose monohydrate water for injection - therapeutic treatment of severe hypoglycaemic reactions, which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. to prevent the occurrence of secondary hypoglycaemia, oral carbohydrate should be given to restore the hepatic glycogen when the patient has responded to the treatment. the mechanism and hence treatment of sulfonylurea-induced hypoglycaemia differs from that of severe insulin-induced hypoglycaemia in some important ways. consciousness should preferably be restored by the administration of intravenous glucose. if glucagon is used due to the unavailability of intravenous glucose (e.g. before reaching a hospital) care should be taken to protect against secondary hypoglycaemia with constant monitoring of the patient's blood sugar level by medical personnel. subsequent administration of intravenous glucose may be required.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - glucagon (unii: 76la80ig2g) (glucagon - unii:76la80ig2g) - become familiar with the following instructions before an emergency arises. do not use this kit after date stamped on the vial of glucagon. if you have questions concerning the use of this product, consult a doctor, nurse or pharmacist. make sure that your relatives or close friends know that if you become unconscious, medical assistance must always be sought. glucagon may have been prescribed so that members of your household can give the injection if you become severely hypoglycemic and are unable to take sugar by mouth. if you are unconscious, glucagon can be given while awaiting medical assistance. show your family members and others where you keep this kit and how to use it. they need to know how to use it before you need it. they can practice giving a shot by giving you your normal insulin shots. it is important that they practice. a person who has never given a shot probably will not be able to do it in an emergency. important - act quickly. prolonged unconsciousness may be harmful. - these simple inst

Malta - English - Medicines Authority

novonordisk a/s novo alle, dk – 2880 bagsvaerd, denmark - glucagon - powder and solvent for solution for injection - glucagon - pancreatic hormones

Malta - English - Medicines Authority

novonordisk a/s novo alle, dk – 2880 bagsvaerd, denmark - glucagon - powder and solvent for solution for injection - glucagon - pancreatic hormones

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - glucagon (unii: 76la80ig2g) (glucagon - unii:76la80ig2g) - for the treatment of severe hypoglycemia: glucagon is indicated as a treatment for severe hypoglycemia (low blood sugar) which may occur in patients with diabetes mellitus. because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient. for use as a diagnostic aid: glucagon is indicated as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon when diminished intestinal motility would be advantageous. glucagon is as effective for this examination as are the anticholinergic drugs. however, as use of glucagon in combination with anticholinergic drugs may result in increased side effects, the use of glucagon in combination with anticholinergic drugs is not recommended. glucagon is contraindicated in patients with known hypersensitivity to it or in patients with known pheochromocytoma. glucagon for injecti

United States - English - NLM (National Library of Medicine)

eli lilly and company - glucagon (unii: 76la80ig2g) (glucagon - unii:76la80ig2g) - baqsimi™ is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 4 years and above. baqsimi is contraindicated in patients with: - pheochromocytoma because of the risk of substantial increase in blood pressure [see warnings and precautions (5.1)] - insulinoma because of the risk of hypoglycemia [see warnings and precautions (5.2)] - known hypersensitivity to glucagon or to any of the excipients in baqsimi. allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension [see warnings and precautions (5.3)] risk summary available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestat

United States - English - NLM (National Library of Medicine)

amphastar pharmaceuticals, inc. - glucagon (unii: 76la80ig2g) (glucagon - unii:76la80ig2g) - baqsimi™ is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 4 years and above. baqsimi is contraindicated in patients with: - pheochromocytoma because of the risk of substantial increase in blood pressure [see warnings and precautions (5.1)] - insulinoma because of the risk of hypoglycemia [see warnings and precautions (5.2)] - known hypersensitivity to glucagon or to any of the excipients in baqsimi. allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension [see warnings and precautions (5.3)] risk summary available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. in a rat reproduction study, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 40 times the human dose, based on body surface area (mg/m2 ) (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data in pregnant rats given animal sourced glucagon twice-daily by injection at doses up to 2 mg/kg (up to 40 times the human dose based on body surface area extrapolation, mg/m2 ) during the period of organogenesis, there was no evidence of increased malformations or embryofetal lethality. risk summary there is no information available on the presence of glucagon in human or animal milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. however, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is therefore, unlikely to cause harm to an exposed infant. the safety and effectiveness of baqsimi for the treatment of severe hypoglycemia in patients with diabetes have been established in pediatric patients ages 4 years and above. use of baqsimi for this indication is supported by evidence from a study in 48 pediatric patients from 4 to <17 years of age with type 1 diabetes mellitus. [see clinical studies (14.2)] . the safety and effectiveness of baqsimi have not been established in pediatric patients younger than 4 years of age. clinical studies of baqsimi did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. limited clinical trial experience has not identified differences in responses between the elderly and younger patients. instructions for use baqsimi® (glucagon) nasal powder 3 mg read the instructions for use for baqsimi before using it. baqsimi is used to treat very low blood sugar (severe hypoglycemia) that may cause you to need help from others. you should make sure you show your caregivers, family and friends where you keep baqsimi and explain how to use it by sharing these instructions. they need to know how to use baqsimi before an emergency happens.  tube and device parts important information to know - do not remove the shrink wrap or open the tube until you are ready to use it. - if the tube has been opened, baqsimi could be exposed to moisture. this could cause baqsimi not to work as expected. - do not push the plunger or test baqsimi before you are ready to use it. - baqsimi contains 1 dose of glucagon nasal powder and cannot be reused. - baqsimi is for nasal (nose) use only. - baqsimi will work even if you have a cold or are taking cold medicine. preparing the dose - remove the shrink wrap by pulling on red stripe. - open the lid and remove the device from the tube. caution: do not press the plunger until ready to give the dose. giving the dose - hold device between fingers and thumb. - do not push plunger yet. - insert tip gently into one nostril until finger(s) touch the outside of the nose. -  push plunger firmly all the way in. - dose is complete when the green line disappears. after giving baqsimi - call for emergency medical help right away. - if the person is unconscious turn the person on their side. - throw away the used device and tube. - encourage the person to eat as soon as possible. when they are able to safely swallow, give the person a fast acting source of sugar, such as juice. then encourage the person to eat a snack, such as crackers with cheese or peanut butter. - if the person does not respond after 15 minutes, another dose may be given, if available. storage and handling - do not remove the shrink wrap or open the tube until you are ready to use it. - store baqsimi in the shrink wrapped tube at temperatures up to 86º f (30ºc ). - replace baqsimi before the expiration date printed on the tube or carton. other information - caution: replace the used baqsimi right away so you will have a new baqsimi in case you need it. - keep baqsimi and all medicines out of the reach of children. for questions or more information about baqsimi - call your healthcare provider - call amphastar pharmaceuticals, inc. 1-800-423-4136 - visit www.baqsimi.com baqsimi is a registered trademark of amphastar pharmaceuticals, inc. marketed by: amphastar pharmaceuticals, inc. rancho cucamonga, ca 91730, u.s.a copyright © 2023, amphastar pharmaceuticals, inc. this instructions for use has been approved by the u.s. food and drug adminstration issued: may, 2023 678351ama/5-23

Ireland - English - HPRA (Health Products Regulatory Authority)

novo nordisk a/s - glucagon - powder and solvent for solution for injection - 1 milligram(s) - glycogenolytic hormones; glucagon